Armenia vs Kazakhstan: Average cost of multi drug-resistant tuberculosis treatment
Armenia
2,970 constant 2022 US$
in 2024
Kazakhstan
3,398 constant 2022 US$
in 2023
Armenia rank
16th
Kazakhstan rank
13th
Average cost of multi drug-resistant tuberculosis treatment over time
- Armenia
- Kazakhstan
How they compare
Kazakhstan currently reports 3,398 constant 2022 US$ against 2,970 constant 2022 US$ in Armenia, a difference of 428 constant 2022 US$.
That makes Kazakhstan's figure about 1.1 times Armenia's.
Across all 5 years both countries report, Armenia has been ahead every year.
Armenia ranks 16th and Kazakhstan ranks 13th of 92 countries.
Armenia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Armenia | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,850 constant 2022 US$ | 2,145 constant 2022 US$ | 2,705 constant 2022 US$ | Armenia |
| 2020s | 4,502 constant 2022 US$ | 2,932 constant 2022 US$ | 1,570 constant 2022 US$ | Armenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Armenia or Kazakhstan?
- Kazakhstan, at 3,398 constant 2022 US$ against 2,970 constant 2022 US$ in Armenia as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Armenia and Kazakhstan?
- 428 constant 2022 US$, with Kazakhstan ahead.
- How many years of comparable data are there for Armenia and Kazakhstan?
- 5 years are reported by both, from 2019 to 2023.
- How do Armenia and Kazakhstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Armenia ranks 16th and Kazakhstan ranks 13th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.